Azacitidine: all 480 studies that test it
Page 4 of 5. Open to participants first (142), then studies with results posted, then the rest; newest registration first within each.
- A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid LeukemiaActive, not recruitingNCT05520567Phase 1/2
- Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia PatientsCompletedNCT05471700Not applicable
- Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP PatientsCompletedNCT05433532Phase 2
- Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic SyndromeActive, not recruitingNCT05379166Phase 2
- Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid LeukemiaStatus unknownNCT05362942Phase 2
- Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML PatientsTerminatedNCT05361057Phase 2
- Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After TransplantationStatus unknownNCT05266274Not applicable
- Venetoclax in Patients With MDS or AML in Relapse After AHSCTActive, not recruitingNCT05226455Phase 1/2
- Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly PatientsCompletedNCT05188326Phase 3
- A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.CompletedNCT05155709Phase 1
- Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in ChinaActive, not recruitingNCT05144243Phase 4
- PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesTerminatedNCT05107856Phase 1
- Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell LymphomaCompletedNCT05058755Not applicable
- Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AMLStatus unknownNCT05053425Not applicable
- Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AMLCompletedNCT05048615Phase 2
- Pharmacokinetics, Tolerability and Safety of NEX-18aCompletedNCT05048498Phase 1
- Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLHStatus unknownNCT05008666Phase 2
- Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid LeukemiaTerminatedNCT04964505Phase 1
- Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults with Recurrent or Residual Posterior Fossa EpendymomaCompletedNCT04958486Early Phase 1
- Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic SyndromeTerminatedNCT04912063Phase 1
- Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell LymphomaStatus unknownNCT04899414Phase 2
- Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid LeukemiaStatus unknownNCT04867928Phase 2
- Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.TerminatedNCT04866056Phase 1/2
- Venetoclax + Azacitidine vs. Induction Chemotherapy in AMLActive, not recruitingNCT04801797Phase 2
- A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)TerminatedNCT04755244Phase 1
- Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid LeukemiaCompletedNCT04742101Phase 1/2
- Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT04734990Phase 1/2
- A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMMLActive, not recruitingNCT04730258Phase 1/2
- Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years OldCompletedNCT04687761Phase 1/2
- Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial MalignanciesWithdrawnNCT04648826Phase 1/2
- Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaTerminatedNCT04550442Phase 1/2
- A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDSSuspendedNCT04511975Phase 1
- Azacitidine and Homoharringtonine in JMMLStatus unknownNCT04505995Not applicable
- Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL MutationsActive, not recruitingNCT04493138Phase 1/2
- Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AMLStatus unknownNCT04490707Phase 3
- Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDSSuspendedNCT04485065Phase 1
- Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional ChemotherapyStatus unknownNCT04480125Phase 2
- IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMMLCompletedNCT04372433Phase 1
- Study of Azacitidine Combined With Homoharringtonie Based Regimens in AMLStatus unknownNCT04248595Phase 2
- A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive TreatmentCompletedNCT04241549Phase 1
- Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCTStatus unknownNCT04216355Phase 2/3
- Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous LeukemiaTerminatedNCT04172844Phase 1
- Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic SyndromeTerminatedNCT04160052Phase 1/2
- Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AMLCompletedNCT04139434Phase 1
- Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant SettingActive, not recruitingNCT04128501Phase 2
- Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk MyelodysplasiaWithdrawnNCT04128020Phase 1
- IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaActive, not recruitingNCT04086264Phase 1/2
- AZA + Venetoclax as Maintenance Therapy in Patients With AML in RemissionTerminatedNCT04062266Phase 2
- PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT04022785Phase 1
- Azacytidine During Anti-tuberculosis TherapyWithdrawnNCT03941496Phase 1/2
- Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML PatientsWithdrawnNCT03932318Phase 1/2
- PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISISCompletedNCT03895671Phase 2
- Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03862157Phase 1/2
- Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell TransplantationActive, not recruitingNCT03843528Phase 1
- Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AMLStatus unknownNCT03825367Phase 1/2
- MRD-guided Treatment in NPM1mut AML PatientsTerminatedNCT03769532Phase 2
- Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaStatus unknownNCT03719989Phase 2
- Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)WithdrawnNCT03699384Phase 1/2
- Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 MutationActive, not recruitingNCT03666559Phase 2
- Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable OsteosarcomaActive, not recruitingNCT03628209Phase 1
- Study of the Safety and Efficacy of APR-246 in Combination With AzacitidineCompletedNCT03588078Phase 1/2
- Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa EpendymomaCompletedNCT03572530Phase 1
- Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT03513484Phase 1
- A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic SyndromeWithdrawnNCT03486353Phase 2
- Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid LeukemiaTerminatedNCT03483948Phase 1
- TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic AcidCompletedNCT03397173Phase 2
- Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2CompletedNCT03338348Phase 2
- A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction ChemotherapyCompletedNCT03298516Phase 1
- COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid TumorsCompletedNCT03206021Phase 1
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03164057Phase 2
- Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for LymphomaStatus unknownNCT03161223Phase 1/2
- CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaCompletedNCT02995655Phase 1
- A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory DisordersCompletedNCT02985190Phase 2
- A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)CompletedNCT02966782Phase 1
- Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AMLTerminatedNCT02942758Phase 2
- A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)CompletedNCT02942290Phase 1
- Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa EpendymomaCompletedNCT02940483Early Phase 1
- A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)WithdrawnNCT02835794Phase 1/2
- Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)WithdrawnNCT02829840Phase 1/2
- Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic MelanomaCompletedNCT02816021Phase 2
- Study of Azacitidine and Durvalumab in Advanced Solid TumorsCompletedNCT02811497Phase 2
- Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic SyndromeWithdrawnNCT02783547Phase 1
- Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AMLCompletedNCT02750995Phase 1
- Azacitidine in Haploidentical Donor Hematopoietic Cell TransplantationTerminatedNCT02750254Phase 1
- Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed LymphomaWithdrawnNCT02701673Phase 1/2
- Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic SyndromeCompletedNCT02553941Phase 1
- Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT02543879Phase 1
- Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic SyndromeActive, not recruitingNCT02530463Phase 2
- A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic SyndromesCompletedNCT02508870Phase 1
- Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by AzacytidineStatus unknownNCT02489929Not applicable
- Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCTCompletedNCT02472691Phase 2
- A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.CompletedNCT02450877Phase 2
- Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)CompletedNCT02447666Phase 2
- A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome PatientsCompletedNCT02323139Phase 1
- Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02319135Phase 3
- Azacytidine Plus FLAG for Relapsed or Refractory AMLStatus unknownNCT02275663Phase 2
- Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDSWithdrawnNCT02204020Phase 2
- Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)TerminatedNCT02203773Phase 1
- Window Trial 5-aza in HNSCC, T-tareCompletedNCT02178072Phase 1
- Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid MalignanciesCompletedNCT02129101Phase 1